Page 14 - 2 Director Reports (Annexure) 2021.cdr

60-61
patent, which was granted in US as US filed as IN201911042344.
10,626,093, is in advanced stages in
• Indian Patent (Complete Specification) titled
Europe.
"Novel processes for the preparation of
• Rosuvastatin Calcium Patent entitled "Novel polymorphic form H3 of Apixaban" was filed
polymorphic forms of Sitagliptin phosphate as IN202011000968.
and processes thereof" is likely to be granted
• Indian Patent (Complete Specification) titled
by Indian Patent Office soon as all necessary "Improved Process for the Preparation
communication is done.
Ertugliflozin L-Pyroglutamate and its
• Indian Patent (Complete Specification) titled I n t e r m e d i a t e s " w a s f i l e d
"Process for the preparation of Rupatadine IN202011001308.
Fumarate Form A" was filed as • Indian Patent (Complete specification) titled
IN201911020274.
"Improved Processes for the Preparation of
• Indian Patent application titled "Novel Edoxaban Tosylate and its Intermediates"
processes for Crystalline Empagliflozin" was was filed as IN202011009865.
filed as IN202011022352.
• Indian Patent (Complete specification) titled
• Indian Patent application titled "Improved "Improved Processes for the preparation as
Processes for removal of Linagliptin Dimer well as purification of Vortioxetine
Impurity" was filed as IN202011032689. Hydrobromide and New Polymorphs
thereof" was filed as IN 202011009866.
• Indian Patent application titled "Preparation
of Amorphous Apixaban by Spray Drying" • New Products developed & launched with
was filed as IN202011050699. high market potential including
Hydroxychloroquine tablets & various Hand
• Indian Patent application titled "Preparation
Sanitizers in Covid Pandemic situation
of Amorphous Linagliptin by Spray Drying"
served country in worst situation.
was filed as IN202111000551.
• 20 New products with High market potential
• Indian Patent application titled "Preparation
launched with various therapeutic category
of Amorphous Empagliflozin by Spray
in the market.
Drying" was filed as IN202111000552.
• Robust formulation development &
• Indian Patent application titled "Preparation
commercial with improved Quality of
of Amorphous Edoxaban Tosylate by Spray
Drying" was filed as IN202111001192. pharmaceutical products via mandatory
stability studies of drug product at
• Indian Patent application titled "New Formulation Development stage to bring
polymorphic form of vortioxetine down market complaints to Zero level with
Hydrobromide & novel processes thereof" high acceptance in market.
was filed as IN202111007325.
• Process changes from critical to simplified
• Indian Patent application titled "Improved i.e., by-passing drying process through DC
Processes for the preparation as well as (direct compression process) saving time
purification of Brexpiprazole & Acid Salts leading to reduced cost of products.
thereof" was filed as IN202111010850.
• Cost reduction in different formulations by
• Indian Patent application titled "Novel reducing tablet weight via excipient qty &
amine salts of Saroglitazar, Processes Grades, solvents replacement with water in
thereof & Novel process for preparation of manufacturing process, without affecting
Amorphous Saroglitazar" was filed as the quality parameters ensured by
IN202111012212. Accelerated stability studies, such as:
• Indian Patent application titled "An Rosuvastatin 10/20/40 mg Tablets,
improved, eco-friendly & commercially Pantoprazole 40 mg DR tablet, Etoricoxib
viable process for the preparation of a key 60,90,120 mg tablets, Loratadine tablets 10
intermediate of atorvastatin calcium" was mg, Telmisartan 40 mg+Hydrochlorthiazide
filed as IN202111017012. 12.5 Bilayer tablets,Telmisartan 40 mg +
Hydrochlorthiazide 12.5+ Amlodipine 5 mg
• Indian Patent (Complete Specification) titled
bilayered tablets, Bisacodyl GR tablets 5 mg,
"Process for Purification of Apixaban" was
Pioglitazone 15/30 mg, Ramipril 2.5 & 5 mg, • Commercialization of Vonoprazan
Azithromycin 250/500 tablets, Clopidogrel Fumarate & Febuxostat is being planned.
75 mg tablets, Ofloxacin 200 mg,
• Further backward integration for key raw
Montelukast 10 mg tablet, Sertaline 50 mg
materials of Empagliflozin is being planned
tablet cost reduction through above
for cost reduction & process extension for
mentioned processes.
regulation requirement in certain countries
3) Future plan of action: such as china.
The company continues to carry on various R&D • Commercialization of Candesartan is
a s initiatives and is regularly upgrades its planned after its development from basic
capabilities to stay ahead of the demanding raw materials.
market requirements. The R&D work is focused • To focus on in-house API formulations for
on:
domestic and export markets.
• New drugs like Levothyroxine Sodium in
• To set up ADL facility for Domestic & ROW
Hormonal replacement therapy, Apremilast
market to support Formulation development
in Psoriatic arthritis Category, Enzalutamide
activities.
in Anti-Cancer Category, Bempedoic Acid in
• To set up new R&D center for API and ARD
Anti-Lipemic category, Upadacitinib &
Baricitinib for Rheumatoid Arthritis facility for formulations for US & other
Category, Tafamidis Meglumine in regulatory markets.
Cardiovascular Category, are being • Upgradation/ modification of existing
considered for development. formulation block to get WHO approval for
• New drugs like Paliperidone Palmitate in domestic & ROW market.
Anti-psychotic Category, Tofacitinib in Anti-
• Technology/Dossier development for US,
Arthritis/immunosuppressant category,
other regulatory markets & ROW market.
Saroglitazar magnesium in Anti-diabetic,
4) Imported Technology (imported during last
Vonoprazan fumarate in Anti-Ulcerative,
3 years reckoned from beginning of the
Elagolix sodium in GnRH antagonist
financial year)
category are in advanced stages of
development. Morepen is looking forward towards marketing
of a new imported Anti-COVID19 vaccine
• Development of Various drug candidates technology in collaboration with an
like Dimenhydrinate in Anti-Emetic
category, Amlodipine Besylate in international company.
5) Expenditure incurred on Research and
Cardiovascular Category, Divalproex Development (R&D)
Sodium in Anti-Epileptic category, Ezetimibe
in Anti-Lipemic Category are in advanced The Company has incurred a total expenditure
stages toward ANDA Filing for US. of Rs. 561.28 Lakhs, in comparison to
expenditure of Rs. 253.45 Lakhs in the previous
• Looking forward to developing more than year (including capital and revenue expenses),
50 products under Biotech category which
towards Research and Development.
includes Global Top sellers key Monoclonal
antibodies, Anti-Cancer molecules, C. FOREIGN EXCHANGE EARNINGS AND OUTGO
Enzymes, Vaccines, male & Female
hormonal drugs & Immunosuppressant The information on earnings and outgo of foreign
Drugs. exchange is given in notes to Financial Statements
(Standalone) under note no. 30.
For and on behalf of Board of Directors
Sushil Suri
Place: New Delhi (Chairman & Managing Director)
th
DIN: 00012028
Date: 27 July, 2021